Sarcoma Accelerator Consortium
Developing precision medicine
for patients with sarcomas
Funding Partners
Sarcoma Accelerator Consortium
Developing precision medicine
for patients with sarcomas
Funding Partners
Our mission is to improve survival rates in patients with high-risk sarcomas
Our mission is to improve survival rates in patients with high-risk sarcomas
The Sarcoma Accelerator Consortium comprise a team of dedicated clinicians and researchers in the UK, Italy, and Spain, who are collaborating on an ambitious programme to develop personalised treatments for a group of rare cancers - soft tissue sarcomas.
This programme aims to develop a digital hub of clinical and research data from patients with high-risk soft tissue sarcomas to help predict responses to drugs using tools such as artificial intelligence. We will also work towards generating preclinical models that shed light on the biological processes impacting tumour response to therapy in the laboratory.
The Sarcoma Accelerator Consortium comprise a team of dedicated clinicians and researchers in the UK, Italy, and Spain, who are collaborating on an ambitious programme to develop personalised treatments for a group of rare cancers - soft tissue sarcomas.
This programme aims to develop a digital hub of clinical and research data from patients with high-risk soft tissue sarcomas to help predict responses to drugs using tools such as artificial intelligence. We will also work towards generating preclinical models that shed light on the biological processes impacting tumour response to therapy in the laboratory.
Together we will develop precision medicine for patients with sarcomas
